EP3302464A4 - Verwendung von cannabinoiden zur behandlung von augenentzündungen und/oder schmerzen - Google Patents

Verwendung von cannabinoiden zur behandlung von augenentzündungen und/oder schmerzen Download PDF

Info

Publication number
EP3302464A4
EP3302464A4 EP16799004.3A EP16799004A EP3302464A4 EP 3302464 A4 EP3302464 A4 EP 3302464A4 EP 16799004 A EP16799004 A EP 16799004A EP 3302464 A4 EP3302464 A4 EP 3302464A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
pain
treatment
ocular inflammation
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16799004.3A
Other languages
English (en)
French (fr)
Other versions
EP3302464A1 (de
Inventor
Mary Lynch
Melanie KELLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panag Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/722,991 external-priority patent/US9549906B2/en
Application filed by Individual filed Critical Individual
Publication of EP3302464A1 publication Critical patent/EP3302464A1/de
Publication of EP3302464A4 publication Critical patent/EP3302464A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16799004.3A 2015-05-27 2016-05-27 Verwendung von cannabinoiden zur behandlung von augenentzündungen und/oder schmerzen Pending EP3302464A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/722,991 US9549906B2 (en) 2013-11-20 2015-05-27 Compositions and methods for treatment of ocular inflammation and/or pain
PCT/CA2016/050603 WO2016187722A1 (en) 2015-05-27 2016-05-27 Use of cannabinoids in the treatment of ocular inflammation and/or pain

Publications (2)

Publication Number Publication Date
EP3302464A1 EP3302464A1 (de) 2018-04-11
EP3302464A4 true EP3302464A4 (de) 2019-01-23

Family

ID=57395729

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16799004.3A Pending EP3302464A4 (de) 2015-05-27 2016-05-27 Verwendung von cannabinoiden zur behandlung von augenentzündungen und/oder schmerzen

Country Status (2)

Country Link
EP (1) EP3302464A4 (de)
WO (1) WO2016187722A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046850A1 (en) * 2017-09-02 2019-03-07 Scientific Holdings, Llc MODULATORS OF TETRAHYDROCANNABINOL
EP3643303A1 (de) * 2018-10-22 2020-04-29 InnovativeHealth Group SL Verbindungen zur verwendung bei der behandlung oder prävention von fibrotischen erkrankungen; pharmazeutische, kosmetische zusammensetzungen und verwendungen davon
CA3171726A1 (en) * 2020-08-21 2022-02-24 Altus Formulation Inc. Dual analgesic/anti-inflammatory compositions comprising cb2 receptor agonists, combinations, and methods of use thereof
CN113491681A (zh) * 2021-08-11 2021-10-12 无锡诺平医药科技有限公司 大麻素分子cbg在制备炎症性疼痛药物中的应用及药用制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2432312A (en) * 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
WO2015074137A1 (en) * 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016187722A1 *

Also Published As

Publication number Publication date
WO2016187722A1 (en) 2016-12-01
EP3302464A1 (de) 2018-04-11

Similar Documents

Publication Publication Date Title
EP3684353A4 (de) Topische formulierungen von cannabinoiden und ihre verwendung zur schmerzbehandlung
EP3554401A4 (de) Augenbehandlungsvorrichtungen und zugehörige verfahren zur verwendung
GB2568809B (en) Use of cannabinoids in the treatment of epilepsy
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
GB2568471B (en) Use of cannabinoids in the treatment of epilepsy
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
IL283372A (en) Use of cannabinoids to treat epilepsy
EP3325473A4 (de) Verbindungen und verwendungen davon in der behandlung von krebs und anderen medizinischen störungen
IL274769A (en) Use of cannabinoids in the treatment of epilepsy
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
EP3137116A4 (de) Dendrimerzusammensetzungen und deren verwendung bei der behandlung von erkrankungen des auges
EP3576738A4 (de) Verwendung von gaboxadol zur behandlung von tinnitus
EP3236992A4 (de) Peptide und deren verwendung bei der behandlung der haut
GB201703115D0 (en) Use of cannabinoids in the treatment of leukaemia
EP3169321A4 (de) Propolis und extrakte daraus zur behandlung von hautkarzinomen und verbesserung der hautgesundheit
EP3648762A4 (de) Verwendung von gaboxadol bei der behandlung von diabetes und verwandten erkrankungen
IL270978B (en) Grape skin for use in the treatment of dysbiosis
EP3302464A4 (de) Verwendung von cannabinoiden zur behandlung von augenentzündungen und/oder schmerzen
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
EP3452015A4 (de) Zusammensetzungen und verfahren zur behandlung der entzündung oder infektion des auges
EP3344233A4 (de) Transdermale formulierungen zur abgabe von doxycyclin und deren verwendung bei der behandlung von auf doxycyclin ansprechenden erkrankungen und leiden
EP3380112A4 (de) Peptide und deren verwendung bei der behandlung von haar
EP3710010A4 (de) Verwendung von hm4di bei der behandlung von anfallserkrankungen
EP3341481A4 (de) Microrna-328-antisense-zusammensetzung und therapeutische verwendung
EP3398596A4 (de) Ingenolverbindungen und verwendung davon in der anti-hiv-latenzbehandlung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 29/00 20060101ALI20181214BHEP

Ipc: C07D 311/80 20060101ALI20181214BHEP

Ipc: A61P 27/02 20060101ALI20181214BHEP

Ipc: A61K 31/05 20060101ALI20181214BHEP

Ipc: A61K 31/352 20060101AFI20181214BHEP

Ipc: A61K 45/06 20060101ALI20181214BHEP

Ipc: A61P 25/02 20060101ALI20181214BHEP

Ipc: C07C 39/23 20060101ALI20181214BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANAG PHARMA INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KELLY, MELANIE

Inventor name: LYNCH, MARY

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS